The objective of the present study was to evaluate the Taipan snake venom time (TSVT) assay in the detection of lupus anticoagulant in patients receiving or not receiving oral vitamin K antagonists. Blood samples were collected from individuals requiring investigation for the presence of a lupus anticoagulant. The TSVT test was run in parallel with the dilute Russell viper venom time (dRVVT) assay and anticardiolipin antibody assays. Results were assessed by Bayesian statistics. Two thousand and five plasma samples were obtained from 1335 individuals. One thousand, one hundred and eleven individuals were not receiving oral vitamin K antagonists; of these, 451 had a lupus anticoagulant by conventional testing, and the TSVT showed a sensitivity of 22%, specificity of 98%, positive predictive value of 80%, negative predictive value of 78%, positive likelihood ratio of 12.3 and a negative likelihood ratio of 0.790. Two hundred and ten of the 224 patients receiving oral vitamin K antagonists were known to have a persistent lupus anticoagulant prior to oral anticoagulation. In this setting, TSVT had a sensitivity of 39% and specificity of 93%, but the dRVVT had a 50% false-positive rate, which meant that despite having a higher sensitivity at 61% than the TSVT, its specificity was only 53%. TSVT is a specific but insensitive assay for the lupus anticoagulant in individuals not receiving oral vitamin K antagonists, when assessed against the dRVVT as the gold standard. It can be argued that despite the TSVT's poor sensitivity in patients taking oral vitamin K antagonists, its high specificity and positive predictive value make it a preferable assay to the dRVVT to diagnose lupus anticoagulant in this group.

Download full-text PDF

Source
http://dx.doi.org/10.1097/mbc.0b013e3283256037DOI Listing

Publication Analysis

Top Keywords

lupus anticoagulant
28
oral vitamin
24
receiving oral
20
vitamin antagonists
20
individuals receiving
12
taipan snake
8
snake venom
8
receiving receiving
8
venom time
8
patients receiving
8

Similar Publications

Pregnancy in women with lupus, particularly those with lupus nephritis (LN), carries an increased risk of adverse outcomes. Women with active LN at the time of conception are at a high risk of poor maternal and fetal outcomes. Recent studies indicate that even in the presence of quiescent disease, factors such as hypertension and positive lupus anticoagulant are predictors of worse pregnancy outcomes.

View Article and Find Full Text PDF

Prolongation of the activated partial thromboplastin time (aPTT) may signify an intrinsic factor deficiency or the presence of an inhibitor of coagulation, potentially placing a patient at increased risk for bleeding. However, a contact factor (ie, factor XII, prekallikrein, and high molecular weight kininogen) deficiency, which may also cause a prolonged aPTT, is not associated with clinical bleeding. A 71-year-old female had an isolated prolonged aPTT discovered during preoperative laboratory testing.

View Article and Find Full Text PDF

Positivity of antiphosphatidylserine/prothrombin antibodies identifies a subgroup of more severe antiphospholipid syndrome patients.

Clin Exp Rheumatol

December 2024

Laboratoire d'Immunologie, AP-HP, Hôpital Européen Georges Pompidou, Paris; and Inflammation, Complement, and Cancer, Université Paris Cité, INSERM, UMRS 1138, Cordeliers Research Center, Team Paris, France.

Objectives: Antiphospholipid syndrome (APS) is an autoimmune disease combining the occurrence of thrombotic and/or obstetric events with the persistent presence of antiphospholipid antibodies (i.e. lupus anticoagulant (LA), anti-cardiolipin (aCL) and anti-beta-2-glycoprotein I (aβ2GPI) antibodies).

View Article and Find Full Text PDF

Risk factors associated with pregnancy outcomes in patients with recurrent pregnancy loss after treatment.

BMC Pregnancy Childbirth

December 2024

Department of Obstetrics & Gynecology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.

Background: The treatment for recurrent pregnancy loss (RPL) has been addressed in international guidelines. However, limited studies have investigated the risk factors associated with pregnancy and live birth outcomes in patients with RPL after treatment. The objective of this study was to offer a comprehensive assessment of the risk factors for pregnancy loss in patients with a history of RPL following therapeutic interventions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!